Quantum BioPharma Ltd. January 2025 Form 6-K Report: Key Financial Insights

Based on the provided section of the financial report, here are the key pieces of information extracted:

1. Filing Type: The document is a Form 6-K, which is used by foreign private issuers to report financial information to the SEC.
2. Reporting Period: The report is for the month of January 2025.
3. Commission File Number: 001-39152, identifying the registrant's filings with the SEC.
4. Registrant Name: Quantum BioPharma Ltd., indicating the company that submitted the report.
5. Principal Executive Office Address:

• 55 University Ave., Suite 1003
• Toronto, Ontario M5J2H7, Canada.

6. Annual Report Filing Indication: The registrant indicates that it files annual reports under:

• Form 20-F (checked)
• Form 40-F (not checked).

7. Signature Section:

• The report is signed by Donal Carroll, Chief Financial Officer.
• The date of signing is January 17, 2025.

8. Exhibit Index:

• Exhibit 99.1 is a press release linked from the document (fsd_ex991.htm).

Insights:

• The use of Form 6-K suggests that Quantum BioPharma is providing updates or disclosures that are relevant to investors and stakeholders.
• The company's choice to file under Form 20-F indicates that it is a foreign company and adheres to international financial reporting standards.
• The presence of a press release could suggest important developments or announcements that the company wants to communicate to the market.

This report serves as an important tool for investors and analysts looking to understand the company's current status and any recent developments.